Permira has named Dr. Bruno Strigini as a healthcare-focused senior advisor. He is the former president and CEO of Novartis Oncology. Previously, Strigini was president of Europe/Canada at Merck & Co.
Permira, the global private equity firm, has today announced that Dr Bruno Strigini has joined as a Senior Adviser, focusing on healthcare.
Dr Strigini brings over 30 years of experience in healthcare with a successful track record in international executive leadership as President and CEO of Novartis Oncology from 2014 to 2018. He was previously President of Europe/Canada at Merck & Co, and also worked at Schering-Plough, UCB, and SmithKline Beecham, where his roles have included President of International operations, President of Japan and Asia-Pacific, Head of Global Marketing and Business Development, and Managing Director positions.
Dr Strigini currently serves as Chairman of the board of Owkin, a leading AI and machine learning company specialising in healthcare and is a partner at OneHealth Partners, an advisory firm focused on capital raising and strategic transactions in the healthcare sector.
Bruno Strigini holds a Master of Business Administration from IMD Lausanne, Switzerland, a PharmD from the University of Montpellier, France, and a master’s degree in microbiology from Heriot-Watt University, United Kingdom. He has been an elected member of the French academy of Pharmacy since 2012 and in 2014 was awarded an honorary doctorate from UIMP in Spain.
The Permira funds have completed several successful investments in the healthcare sector and have deployed around €2.7bn in the sector to date. The funds recently agreed to acquire Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), reinforcing that pharma remains one of the most attractive investment areas for the Permira funds. Permira had already invested in the space in the past few years with the funds’ investments in Cambrex in 2019, a leading pharma CDMO, Quotient Sciences in the same year, a provider of specialist drug development services and LSNE, a contract development and manufacturing organisation specialising in sterile lyophilisation and fill & finish. Other portfolio companies in the sector include Althea, a leading European independent medical equipment service provider, Corin, a tech enabled orthopaedic implant company and I-Med the leading network of radiology clinics in Australia.
Silvia Oteri, Partner and Head of Healthcare at Permira, says: “Bruno’s knowledge, expertise and network in the pharma space together with his experience in growing sustainable global businesses will help us further strengthen our expertise and network to continue to successfully invest in the space backing successful, complex and disruptive businesses”.
Bruno Strigini added: “I’m delighted to be joining Permira as a Senior Adviser. The team has a strong track record of investing across the healthcare sector and I look forward to helping source and develop interesting proprietary investment opportunities globally”.